Intracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle

Neurooncol Adv. 2023 Mar 21;5(1):vdad026. doi: 10.1093/noajnl/vdad026. eCollection 2023 Jan-Dec.

Hanim I Ozkizilkaya¹, Jason M Johnson², Barbara J O'Brien³, Ian E McCutcheon⁴, Sujit S Prabhu⁴, Amol J Ghia⁵, Gregory N Fuller^{2

6}, Jason T Huse^{1

6}, Leomar Y Ballester^{1

6}

¹ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
² Division of Diagnostic Imaging, Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, USA.
³ Division of Cancer Medicine, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
⁴ Division of Surgery, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
⁵ Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
⁶ Division of Pathology and Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.

No abstract available

Keywords: CREB3L3; EWSR1; FET::CREB fusion; angiomatoid fibrous histiocytoma; intracranial mesenchymal tumor; meningioma.

Grants and funding